PLRX

Rating neutralTentativeAI Memo

Pliant Therapeutics

As of 2026-10-18/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Integrin-targeted delivery platform update • 2026-12-31

Base target: $1 / p=50% prob

Biggest risk

A weak efficacy or safety signal could sharply impair the lead program's value. The company attributed much of the year-over-year reduction in second-quarter R&D expense and net loss to the termination of its prior bexotegrast IPF program, underscoring development risk. SEC-filed company release

Invalidation

Break below $0 or thesis failure.

What would change my mind?

Ahead-of-schedule FORTIFY enrollment and reported responder biomarker changes support continued study, while management projects cash funding into the second half of 2028. Clinical benefit remains unproven in the expansion cohorts. [#PR-EARNINGS-2026-08-11] SEC-filed company release

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-18

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Clinical spending and cash runway
Ahead-of-schedule FORTIFY enrollment and reported responder biomarker changes support continued study, while management projects cash funding into the second half of 2028.
Clinical benefit remains unproven in the expansion cohorts.

BearKey bullets

FORTIFY interim data are expected in 2027; current enrollment and biomarker observations do not establish efficacy or safety in the expansion cohorts.
SEC-filed company release
Management's cash-runway projection could change with trial spending, delays or financing needs.

WatchKey bullets

Integrin-targeted delivery platform update

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $1 (p=50%)

Target spread vs base: +100% / -61%

Scenario probabilities

Bull Target: $2 (p=25%)Base Target: $1 (p=50%)Bear Target: $0 (p=25%)

Commentary

Cautious monitoring view despite the packet's positive directional prior: coverage is low, the decisive clinical readout is expected in 2027, and peer comparability is limited. No verified recent price reaction or analyst target revisions were available. Zero-valued sentiment fields denote unavailable measurements, not observed neutral readings.

As of 2026-10-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Clinical spending and cash runway

Scenarios

Bull Target (Scenario probability)

$2 / p=25% prob

Base Target (Scenario probability)

$1 / p=50% prob

Bear Target (Scenario probability)

$0 / p=25% prob

Analysis 2026-10-18 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Integrin-targeted delivery platform update
Pliant plans to disclose initial treatment indications and a path forward in the second half of 2026. Its siRNA-delivery proof-of-concept work remains preclinical, so an update may not establish clinical value. [#PR-EARNINGS-2026-08-11] SEC-filed company release
Prob 55.00% • Move 12.00% • Priced-in 25.00%
EVENT2027-12-31
FORTIFY interim oncology data
Pliant reported ahead-of-schedule enrollment in the Phase 1b FORTIFY expansion trial of PLN-101095 plus pembrolizumab and expects interim data in 2027. Safety and antitumor activity, rather than enrollment alone, will test the investment case. [#PR-EARNINGS-2026-08-11] SEC-filed company release
Prob 60.00% • Move 25.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Clinical spending and cash runway
2028-07-01
Pliant reported $159.6 million in cash, equivalents and short-term investments at June 30, 2026, and projected funding into the second half of 2028. FORTIFY spending could change that estimate; the balance does not eliminate financing or dilution risk. [#PR-EARNINGS-2026-08-11] SEC-filed company release
Prob 65% • Move 8% • Priced-in 65%

Risks

FORTIFY interim data are expected in 2027; current enrollment and biomarker observations do not establish efficacy or safety in the expansion cohorts. SEC-filed company release
Management's cash-runway projection could change with trial spending, delays or financing needs. SEC-filed company release
The planned delivery-platform update concerns preclinical work and may not provide a clinically validated second program. SEC-filed company release
The prior bexotegrast IPF program was terminated; Pliant's oncology pivot concentrates the clinical thesis on PLN-101095. SEC-filed company release

Peers

Symbol	Summary
BCAX	Mechanistic comparator studying TGF-β inhibition with pembrolizumab. Its first-line head-and-neck program is more advanced and serves a different population from Pliant's ICI-refractory cohorts; it is not a direct valuation peer. Bicara company update
APLM	Clinical-oncology comparator with a Phase 2 NSCLC program, but a different drug target and development path limit valuation comparability. Apollomics company update

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-18

Loading AI feed…

Symbol

Summary

BCAX

Mechanistic comparator studying TGF-β inhibition with pembrolizumab. Its first-line head-and-neck program is more advanced and serves a different population from Pliant's ICI-refractory cohorts; it is not a direct valuation peer. Bicara company update

APLM

Clinical-oncology comparator with a Phase 2 NSCLC program, but a different drug target and development path limit valuation comparability. Apollomics company update